SG11201901762WA - Methods and composition for the prediction of the activity of enzastaurin - Google Patents
Methods and composition for the prediction of the activity of enzastaurinInfo
- Publication number
- SG11201901762WA SG11201901762WA SG11201901762WA SG11201901762WA SG11201901762WA SG 11201901762W A SG11201901762W A SG 11201901762WA SG 11201901762W A SG11201901762W A SG 11201901762WA SG 11201901762W A SG11201901762W A SG 11201901762WA SG 11201901762W A SG11201901762W A SG 11201901762WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- san diego
- enza
- denovo
- biopharma
- Prior art date
Links
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 229950002189 enzastaurin Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111 0111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/045240 Al 08 March 2018 (08.03.2018) W I PO I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: (74) Agent: YIN, Bu et al.; Morrison & Foerster LLP, 12531 C12Q 1/68 (2006.01) High Bluff Drive, Suite 100, San Diego, CA 92130-2040 International Application Number: (US). PCT/US2017/049747 (81) Designated States (unless otherwise indicated, for every International Filing Date: kind of national protection available): AE, AG, AL, AM, 31 August 2017 (31.08.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/382,734 01 September 2016 (01.09.2016) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/414,601 28 October 2016 (28.10.2016) US SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: DENOVO BIOPHARMA LLC [US/US]; 6331 Nancy Ridge Drive, San Diego, CA 92121 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, Inventors: LUO, Wen; c/o Denovo Biopharma LLC, 6331 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Nancy Ridge Drive, San Diego, CA 92121 (US). SUN, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Hong; c/o Denovo Biopharma LLC, 6331 Nancy Ridge Dri-TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, ye, San Diego, CA 92121 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = Title: METHODS AND Overall Survival in Enza + RCHOP Treated Patients Carrying Different .100 90 1 so 70 ? 60 Tri > > I- OD 40 30 20 10 (54) COMPOSITION FOR THE PREDICTION OF THE ACTIVITY OF ENZASTAURIN Figure 3C. S028 First Line Genotypes = = = = _ = = — = i , , I -6- R-CHOPIEnza AA+AB (N=48) * - R-CHOP/Enza BB (N=9) 1 1 1 1 -, AA+AB vs. BB in R-CHOP/Enza Hazard ratio (95% CI): 0.096 (0.019, 0.492) p.0.005 = — = = = _ = 1-1 .4 © N kin ii- c:::: , (57) --- -- GC (e.g., ,-1 The 0 can N by 71- 10 20 30 40 50 60 70 80 Months : The present invention describes biomarkers that have been discovered to correlate with varied individual responses efficacy, adverse effect, and other end points) to enzastaurin, in treating diseases such as, DLBCL, GBM, and other cancer types. newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might not be beneficial, the treatment. [Continued on next page] WO 2018/045240 Al MIDEDIMOMMIDIREEMOMIVEIDEMOIHMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of earlier application (Rule 4.17(iii)) he Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US201662414601P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/049747 WO2018045240A1 (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901762WA true SG11201901762WA (en) | 2019-03-28 |
Family
ID=59923555
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901762WA SG11201901762WA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
| SG10201912134TA SG10201912134TA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912134TA SG10201912134TA (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (en) |
| EP (1) | EP3507384B1 (en) |
| JP (3) | JP7197915B2 (en) |
| KR (1) | KR20190046935A (en) |
| CN (1) | CN109952383B (en) |
| AU (1) | AU2017318669B2 (en) |
| BR (1) | BR112019003951A2 (en) |
| CA (1) | CA3035386A1 (en) |
| JO (1) | JOP20190025A1 (en) |
| MX (1) | MX2019002377A (en) |
| PH (1) | PH12019500422A1 (en) |
| RU (1) | RU2019109011A (en) |
| SG (2) | SG11201901762WA (en) |
| TW (2) | TW202313973A (en) |
| WO (1) | WO2018045240A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (en) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | Methods and composition for the prediction of the activity of enzastaurin |
| CN110496223B (en) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | Pharmaceutical composition for treating non-Hodgkin's lymphoma |
| JP2022500408A (en) * | 2018-09-12 | 2022-01-04 | デノボ バイオファーマ エルエルシー | Combination of Enzastaurin with BTK Inhibitors and Their Use |
| CN111549033B (en) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | Lentivirus-infected human epidermal keratinocyte strain and its construction method and application |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| US20240321421A1 (en) * | 2021-07-23 | 2024-09-26 | Kaohsiung Medical University | Clinical therapeutic drug prediction and recommendation system and method for evaluating efficacy of second-generation hormone drug in treatment of prostate cancer |
| US20230131677A1 (en) * | 2021-10-21 | 2023-04-27 | Toyota Research Institute, Inc. | Systems and methods for predicting the effect of an intervention via machine learning |
| WO2023097197A2 (en) * | 2021-11-23 | 2023-06-01 | Denovo Biopharma Llc | Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy |
| US12474842B2 (en) * | 2021-12-13 | 2025-11-18 | Google Llc | Optimizing data placement based on data temperature and lifetime prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE456367T1 (en) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | PROTEIN KINASE C INHIBITORS |
| AU2001285047A1 (en) | 2000-08-16 | 2002-02-25 | Chiron Corporation | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| WO2007145992A2 (en) | 2006-06-05 | 2007-12-21 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| AU2012212499A1 (en) | 2011-01-31 | 2013-08-22 | Denovo Biomarkers Inc. | Method for discovering pharmacogenomic biomarkers |
| JP2014524735A (en) * | 2011-06-08 | 2014-09-25 | デノボ バイオファーマ （ハンジョウ） リミテッド カンパニー | Methods and compositions for predicting retinoid X receptor modulator activity |
| JOP20190025A1 (en) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | Methods and composition for the prediction of the activity of enzastaurin |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/en unknown
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/en unknown
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en not_active Ceased
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en not_active Ceased
- 2017-08-31 TW TW111122709A patent/TW202313973A/en unknown
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/en unknown
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/en not_active IP Right Cessation
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/en active Active
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/en not_active Ceased
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/en active Active
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
- 2017-08-31 TW TW106129838A patent/TWI771317B/en not_active IP Right Cessation
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/en active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019528705A (en) | 2019-10-17 |
| TW202313973A (en) | 2023-04-01 |
| JP2022173308A (en) | 2022-11-18 |
| WO2018045240A1 (en) | 2018-03-08 |
| CA3035386A1 (en) | 2018-03-08 |
| RU2019109011A3 (en) | 2021-01-22 |
| JP2020188816A (en) | 2020-11-26 |
| AU2017318669B2 (en) | 2023-04-20 |
| TW201812125A (en) | 2018-04-01 |
| SG10201912134TA (en) | 2020-02-27 |
| PH12019500422A1 (en) | 2019-05-27 |
| CN109952383B (en) | 2024-01-05 |
| RU2019109011A (en) | 2020-10-05 |
| EP3507384B1 (en) | 2023-08-30 |
| CN109952383A (en) | 2019-06-28 |
| EP3507384A1 (en) | 2019-07-10 |
| US20230074781A1 (en) | 2023-03-09 |
| JP7197915B2 (en) | 2022-12-28 |
| TWI771317B (en) | 2022-07-21 |
| MX2019002377A (en) | 2019-09-05 |
| US11421280B2 (en) | 2022-08-23 |
| US20190233902A1 (en) | 2019-08-01 |
| KR20190046935A (en) | 2019-05-07 |
| BR112019003951A2 (en) | 2019-06-25 |
| JOP20190025A1 (en) | 2019-02-19 |
| AU2017318669A1 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901762WA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201901961SA (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201805831RA (en) | Neutralization of inhibitory pathways in lymphocytes | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof |